Drugs / ERTEBEREL
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03689543 | May 2019 → Sep 2024 | — | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2 | NCT01874756 | Jun 2013 → Dec 2017 | schizophrenia | Indiana University | Terminated | No outcome recorded |
| Phase 2 | NCT01097707 | Apr 2010 → Oct 2011 | benign prostatic hyperplasia | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERTEBEREL | ChEMBL registry synonym — accepted as the source's own label CHEMBL278703 ↗ |
| Known as | LY500307 | “Lilly Compound LY500307, a selective estrogen receptor (ER) beta agonist” NCT03689543 ↗ |
| Known as | Serba-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL278703 ↗ |
| Action | Activate | “Estrogen receptor beta agonist” CHEMBL278703 ↗1“selective ERβ agonist LY500307” NCT01874756 ↗ |
| Modality | Small molecule | — CHEMBL278703 ↗ |
| Route | Oral | “Administered orally, daily for 24 weeks” NCT01097707 ↗ |
| Target | ESR2 | “Estrogen receptor beta agonist” CHEMBL278703 ↗ |